VEGFA and nonpapillary renal cell carcinoma: In this context, immunotherapy for ccRCC has progressed considerably over the past decade, with new options ranging from cytokine treatments [54] to targeted therapies such as ICB and VEGF tyrosine kinase inhibitors (TKIs) [55, 56].